Maintenance treatment for patients with mantle cell lymphoma: A systematic review and meta-analysis of randomized trials

Liat Vidal, Anat Gafter-Gvili, Martin Dreyling, Michele Ghielmini, Mathias Witzens-Harig, Ofer Shpilberg, Michael Unterhalt, Mathias Rummel, Ronit Gurion

Research output: Contribution to journalArticlepeer-review

Abstract

Current treatment of patient with mantle cell lymphoma (MCL) is insufficient and does not result in cure. To assess the efficacy and safety of maintenance therapy for patients with MCL, we performed a systematic review and meta-analysis of randomized controlled trials. Six trials randomizing 858 patients were included in the meta-analysis. In 5 trials, maintenance therapy consisted of rituximab. The pooled hazard ratio (HR) of death with rituximab maintenance compared to observation was 0.79, 95% CI 0.58 to 1.06 (4 trials, 737 patients). Progression free survival was longer with rituximab maintenance in each of the trials and in the pooled analysis (HR 0.58, 95% CI 0.45-0.73). The risk of neutropenia was higher with maintenance compared to observation risk ratio (RR) 1.31, 95% CI 1.03 to 1.66. None of the trials reported on quality of life outcomes. The grade 3 to 4 infection rate was 7% in each of the treatment groups. The risk of grade 3 to 4 infection was not affected by allocation to maintenance. Rituximab maintenance is recommended after R-CHOP or R-cytarabine-containing induction in the frontline setting for transplant eligible and ineligible patients, and after R-CHOP in the relapse setting. It is unclear if maintenance is of benefit after different induction chemotherapy such as bendamustine or fludarabine. It is too early to conclude on other type of maintenance for MCL patients.

Original languageEnglish
Article numbere136
JournalHemaSphere
Volume2
Issue number4
DOIs
StatePublished - 1 Aug 2018

Fingerprint

Dive into the research topics of 'Maintenance treatment for patients with mantle cell lymphoma: A systematic review and meta-analysis of randomized trials'. Together they form a unique fingerprint.

Cite this